REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational HighlightsPRNewsWire • 05/01/24
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitPRNewsWire • 04/24/24
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDPRNewsWire • 03/28/24
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy DaysPRNewsWire • 03/27/24
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology PlatformSeeking Alpha • 03/11/24
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded WarrantsPRNewsWire • 03/07/24
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIALPRNewsWire • 03/05/24
REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® TrialPRNewsWire • 02/29/24
REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsPRNewsWire • 02/27/24
REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsPRNewsWire • 02/21/24
Strength Seen in Regenxbio (RGNX): Can Its 11.7% Jump Turn into More Strength?Zacks Investment Research • 02/08/24
REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary EndpointPRNewsWire • 02/07/24
REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® TrialPRNewsWire • 02/07/24
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal DeliveryPRNewsWire • 01/16/24
Down -25.53% in 4 Weeks, Here's Why You Should You Buy the Dip in Regenxbio (RGNX)Zacks Investment Research • 01/10/24
U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement LawsuitPRNewsWire • 01/08/24